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Letter to the editor 
The available evidence on safety of intravenous thrombolysis (IVT) in acute ischemic stroke 
patients (AIS) on dual antiplatelet therapy (DAPT) is contradictory1-4. In particular, clinicians 
are uncertain whether to use or refrain from IVT in high risk patients, like those with pre-stroke 
disability who receive DAPT. 
Using data from the prospective Safe Implementation of Treatments in Stroke International 
Stroke Thrombolysis Register (SITS-ISTR), Tsivgoulis et al. recently showed that AIS patients 
on DAPT had similar rates of symptomatic intracerebral hemorrhage (sICH), poor functional 
outcome and mortality after IVT compared to AIS patients without antiplatelet therapy (APT).3 
We think that this analysis, despite the use of propensity score matching, has some limitations. 
First, the analysis excluded patients with pre-stroke disability (pre-stroke modified Rankin 
Scale 2-5), subjects who are more likely to be on DAPT5; second, the dataset had a relatively 
high percentage of missing data (10.5% missing data on APT status, 27% missing data on 3-
month outcome and 7.4% on follow-up neuroimaging). 
Aiming to overcome these limitations and to increase evidence about safety of DAPT in IVT, 
we analysed data from the prospective international Thrombolysis in Ischemic Stroke Patients 
(TRISP) registry. All AIS patients - independently of pre-stroke disability - were included. 
Primary outcomes included sICH (ECASS-II-criteria), poor functional outcome (defined as 
modified Rankin Scale 3-6) and mortality (both at three months). DAPT was defined as any 
combination of antiplatelet therapy with aspirin, clopidogrel, ticagrelor, prasugrel or 
dipyridamole. Patients without APT and without anticoagulants (AC) served as the comparison 
group. We performed logistic regression analyses and calculated odds ratios with 95% 
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confidence intervals [OR, 95%-CI] with adjustment for potentially outcome-modifying 
variables. 
Among 15’156 IVT-treated stroke patients, 8’433 (55.6%) had no APT and no AC, 5’611 
(37.0%) were on single APT, 404 (2.7%) were on DAPT and 708 (4.7%) patients were on AC. 
Data completeness rate was >93% (missing data on APT: 1.1% [n=182]; 3-month outcome: 
3.8% [613]; sICH: 1.4% [218]). The proportion of patients with relevant pre-stroke disability 
(pre-mRS 3-5) in the DAPT group (10.6%) was significantly higher in comparison to patients 
without APT (6.0%). Besides, patients on DAPT were older and more often had cardiovascular 
risk factors than patients without APT. The risk of sICH (ORadjusted 1.29[0.82-2.05]), poor 
outcome (ORadjusted 0.69[0.34-1.20]), and death (ORadjusted 1.48[0.87-2.54]) did not differ 
significantly between IVT-treated patients on DAPT and no APT (Table 1). 
In line with Tsivgoulis et al., our study strongly supports the evidence of not withholding IVT 
in AIS-patients on DAPT using a different, large prospective, multicenter and multinational 
data set. Strengths of our study are the high data completeness and – as a refinement – the 
clarification that safety of IVT in AIS-patients on DAPT applies also to patients with relevant 
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Table 1. Multivariable analysis of outcomes (odds adjusted for variables with p<0.1 in the univariable analysis). Odds ratio (95% 
confidence interval), p-value. 
1: adjusted for age, NIHSS, dual antiplatelet 
2: adjusted for age, sex, stroke to needle time, NIHSS on admission, relevant pre-stroke disability, atrial fibrillation, diabetes, hypertension, hypercholerserolemia, smoking, 
coronary artery disease, prior ischemic stroke, RR systolic on admission, glucose on admission, creatinine on admission, dual antiplatelet 
3: adjusted for age, NIHSS on admission, relevant pre-stroke disability, atrial fibrillation, glucose on admission, creatinine on admission, dual antiplatelet 
 
Abbreviations: 
sICH: symptomatic intracerebral hemorrhage  
APT: antiplatelet therapy 
DAPT: dual antiplatelet therapy 
AC: anticoagulation 
NIHSS: National Institutes of Health Stroke Scale 
 
 Outcome measures 
Putative predicting variables sICH Poor outcome Mortality 
Dual antiplatelet vs no APT and no AC 1.29 (0.82-2.05) 1 p=0.272 0.69 (0.34-1.20) 2 p=0.185 1.48 (0.87-2.54) 3 p=0.150 
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